Related Experiment Video
Updated: May 11, 2026
Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
Melatonin protects against amyloid-β-induced impairments of hippocampal LTP and spatial learning in rats
Xiao-Jie Liu1, Li Yuan, Dong Yang
1Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Abstract:
Alzheimer's disease (AD), the most prevalent neurodegenerative disease in the elderly, leads to progressive loss of memory and cognitive deficits. Amyloid-β protein (Aβ) in the brain is thought to be the main cause of memory loss in AD. Melatonin, an indole hormone secreted by the pineal gland, has been reported to produce neuroprotective effects. We examined whether melatonin could protect Aβ-induced impairments of hippocampal synaptic plasticity, neuronal cooperative activity, and learning and memory. Rats received bilateral intrahippocampal injection of Aβ1-42 or Aβ31-35 followed by intraperitoneal application of melatonin for 10 days, and the effects of chronic melatonin treatment on in vivo hippocampal long-term potentiation (LTP) and theta rhythm and Morris water maze performance were examined. We showed that intrahippocampal injection of Aβ1-42 or Aβ31-35 impaired hippocampal LTP in vivo, while chronic melatonin treatment reversed Aβ1-42- or Aβ31-35-induced impairments in LTP induction. Intrahippocampal injection of Aβ31-35 impaired spatial learning and decreased the power of theta rhythm in the CA1 region induced by tail pinch, and these synaptic, circuit, and learning deficits were rescued by chronic melatonin treatment. These results provide evidence for the neuroprotective action of melatonin against Aβ insults and suggest a strategy for alleviating cognition deficits of AD.
Insights
Melatonin protects against amyloid-beta induced memory loss in Alzheimer's disease models. This study shows melatonin reverses cognitive deficits and improves synaptic plasticity, offering a potential therapeutic strategy.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a leading cause of elderly cognitive decline, primarily linked to amyloid-beta (Aβ) protein accumulation in the brain.
- Melatonin, a pineal gland hormone, exhibits known neuroprotective properties.
- Investigating melatonin's efficacy against Aβ-induced neurotoxicity is crucial for AD therapeutic development.
Purpose of the Study:
- To determine if melatonin can protect against amyloid-beta (Aβ)-induced impairments in hippocampal synaptic plasticity, neuronal activity, and memory.
- To evaluate the therapeutic potential of melatonin in an animal model of Alzheimer's disease.
Main Methods:
- Rats received intrahippocampal injections of Aβ1-42 or Aβ31-35, followed by daily intraperitoneal melatonin administration for 10 days.
- In vivo hippocampal long-term potentiation (LTP), theta rhythm, and Morris water maze performance were assessed to evaluate cognitive and synaptic function.
Main Results:
- Intrahippocampal Aβ1-42 or Aβ31-35 significantly impaired hippocampal LTP.
- Chronic melatonin treatment reversed Aβ-induced impairments in LTP induction.
- Melatonin administration rescued Aβ31-35-induced deficits in spatial learning and reduced theta rhythm power.
Conclusions:
- Melatonin demonstrates significant neuroprotective effects against amyloid-beta insults in the hippocampus.
- Melatonin treatment can reverse synaptic, circuit, and learning deficits associated with Aβ exposure.
- These findings suggest melatonin as a promising therapeutic strategy for mitigating cognitive impairments in Alzheimer's disease.
Related Concept Videos
01:03Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
01:05Long-term Depression